KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.

For advanced non-small cell lung cancer, not suitable for or unwilling to accept the radiotherapy and chemotherapy, targeted therapy patients, is an effective and safe treatment.

The systemic therapy of non-small cell lung cancer (NSCLC) is moving away from the "one-size fits all" empiric chemotherapy to targeted therapy of specific molecular alternations.